SNDX · Syndax Pharmaceuticals Inc · Metrics
$8.72
-0.41 (-4.49%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20
2.18M
Avg daily vol (3M)
2.61M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
SNDX metrics
75 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$8.72
Market cap
$778.67M
Price action
23 metricsPrice change (1W)
-7.7%
Price change (30D)
-35.7%
Price change (3M)
-55.6%
Price change (6M)
-56.3%
Price change (YTD)
-58.5%
Price change (1Y)
-48.9%
Trailing year
Price change (5Y)
-50.9%
52-week high
$25.15
52-week low
$8.56
Change from 52-week high
-65.3%
Change from 52-week low
+1.9%
Annualized volatility
58.0%
Annualized volatility (3M)
77.6%
Implied volatility (30D)
64.5%
IV rank (1Y)
32.3
IV percentile (1Y)
32.9
Beta
0.8
RSI (14D)
28.0
Price vs SMA 50
-38.7%
Price vs SMA 200
-55.1%
Avg volume (3M)
2.61M
Relative volume
0.8
Average dollar volume
$36.58M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
89.30M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.4×
reciprocal yield 41.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.7×
reciprocal yield 37.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
324.4×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
324.4×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-11-02
Profitability
9 metricsGross margin
—
Operating margin
-61.7%
Trailing 12 months
Net margin
-72.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$178.64M
Net income (TTM)
−$209.48M
Trailing 12 months
Diluted EPS (TTM)
$-2.36
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+81.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$289.43M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
+157.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-30.2%
Debt / equity
—
Current ratio
4.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.4
Interest coverage
-44,660.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$83.01M
Latest balance sheet
Cash & equivalents
$135.94M
Total assets
$692.67M
Total debt
$344.10M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$177.36M
Capital expenditures (TTM)
—
R&D (TTM)
$273.00M
SG&A (TTM)
—
Stock compensation (TTM)
$52.61M
R&D / revenue
94.3%
Stock compensation / revenue
18.2%
Ownership (13F)
9 metrics13F filers
237
13F filer change QoQ
-5
Institutional ownership
110.5%
Conviction holders (share of 13F filers)
4.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-10.8%
Holder tenure
14.5
Price vs estimated holder cost
+2.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
18.5%
Short interest
3 metricsShort interest
21.2%
Latest settlement · 6.4 days to cover
Days to cover
6.4d
Short-squeeze score
73 / 100
Insider activity
2 metricsNet insider buying (90D)
−$113,716
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
241 filings
222 filers
Visit website
Investor relations